https://news.medxy.ai/zh/clinical-insights-lipoprotein-deposition/Medxy AIzh2026-08-14T08:33:33-07:00类脂质蛋白沉积症的临床洞察：显微喉外科的疗效与长期结局 https://news.medxy.ai/ja/lipoproteinemia-clinical-findings/Medxy AIja2026-08-14T08:33:05-07:00脂質蛋白症の臨床的知見：マイクロ喉頭手術の有効性と長期転帰 https://news.medxy.ai/vi/lipoid-proteinosis-outcome/Medxy AIvi2026-08-14T08:32:45-07:00Lipoid Proteinosis: Hiệu quả và kết cục dài hạn của microlaryngosurgery https://news.medxy.ai/clinical-insights-into-lipoid-proteinosis-efficacy-and-long-term-outcomes-of-microlaryngosurgery/Medxy AIen2026-08-14T08:31:03-07:00Clinical Insights into Lipoid Proteinosis: Efficacy and Long-Term Outcomes of Microlaryngosurgery https://news.medxy.ai/zh/robotic-vs-laparoscopic-hysterectomy/Medxy AIzh2026-08-14T08:29:39-07:00用客观工具验证机器人与腹腔镜子宫切除术表现：外科卓越迈向标准化 https://news.medxy.ai/ja/robotic-laparoscopic-hysterectomy/Medxy AIja2026-08-14T08:29:24-07:00ロボット支援下・腹腔鏡下子宮摘出術の手術成績を可視化する客観的評価ツールの有用性が明らかに https://news.medxy.ai/vi/robotic-hysterectomy-tools/Medxy AIvi2026-08-14T08:29:02-07:00Nâng tầm phẫu thuật phụ khoa: Công cụ khách quan xác thực hiệu quả trong cắt tử cung hỗ trợ bằng robot và nội soi https://news.medxy.ai/advancing-surgical-excellence-an-objective-tool-validates-performance-in-robotic-and-laparoscopic-hysterectomy/Medxy AIen2026-08-14T08:27:38-07:00Advancing Surgical Excellence: An Objective Tool Validates Performance in Robotic and Laparoscopic Hysterectomy https://news.medxy.ai/zh/adult-adrenal-leukodystrophy/Medxy AIzh2026-08-14T08:25:02-07:00成人脑型肾上腺脑白质营养不良病灶进展的解析：为个体化管理提供依据 https://news.medxy.ai/vi/adrenoleukodystrophy-progress/Medxy AIvi2026-08-14T08:24:17-07:00Giải mã tiến triển tổn thương trong adrenoleukodystrophy thể não ở người lớn để định hướng quản lý cá thể hóa https://news.medxy.ai/unraveling-lesion-progression-in-adult-cerebral-adrenoleukodystrophy-to-inform-personalized-management/Medxy AIen2026-08-14T08:22:45-07:00Unraveling Lesion Progression in Adult Cerebral Adrenoleukodystrophy to Inform Personalized Management https://news.medxy.ai/zh/electrical-stimulation-pelvic-training/Medxy AIzh2026-08-14T08:21:54-07:00电刺激生物反馈联合盆底肌训练：产后盆腔器官脱垂长期疗效如何？ https://news.medxy.ai/ja/postpartum-pelvic-floor/Medxy AIja2026-08-14T08:21:26-07:00産後骨盤臓器脱に対する電気刺激バイオフィードバック併用骨盤底筋訓練の長期効果を検証する https://news.medxy.ai/vi/long-term-impact-of-electrical-stimulation-biofeedback-combined-with-pelvic-floor-muscle-training-for-postpartum-pelvic-organ-prolapse/Medxy AIvi2026-08-14T08:19:15-07:00Đánh giá tác động dài hạn của phương pháp phản hồi sinh học kết hợp kích thích điện và tập luyện cơ sàn chậu đối với tình trạng sa tạng chậu sau sinh https://news.medxy.ai/evaluating-the-long-term-impact-of-electrical-stimulation-biofeedback-combined-with-pelvic-floor-muscle-training-for-postpartum-pelvic-organ-prolapse/Medxy AIen2026-08-14T08:17:38-07:00Evaluating the Long-Term Impact of Electrical Stimulation Biofeedback Combined with Pelvic Floor Muscle Training for Postpartum Pelvic Organ Prolapse https://news.medxy.ai/zh/her2-status-reassessment/Medxy AIzh2026-08-14T08:17:08-07:00复发性宫颈癌中HER2状态再评估：动态表达对靶向治疗的临床意义 https://news.medxy.ai/ja/her2-status-cervical-cancer/Medxy AIja2026-08-14T08:16:50-07:00再発子宮頸癌における HER2 状態を再考する：動的発現が示す分子標的治療への臨床的含意 https://news.medxy.ai/vi/her2-cervical-cancer/Medxy AIvi2026-08-14T08:16:32-07:00Tình trạng HER2 ở ung thư cổ tử cung tái phát: Ý nghĩa lâm sàng của sự biến thiên biểu hiện đối với điều trị nhắm đích https://news.medxy.ai/revisiting-her2-status-in-recurrent-cervical-cancer-clinical-implications-of-dynamic-expression-for-targeted-therapy/Medxy AIen2026-08-14T08:13:19-07:00Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy https://news.medxy.ai/zh/inebilizumab-mg-study/Medxy AIzh2026-08-14T08:12:58-07:00Inebilizumab 显著降低全身型重症肌无力加重与急救治疗需求：来自 III 期 MINT 试验的启示 https://news.medxy.ai/ja/generalized-myasthenia-gravis/Medxy AIja2026-08-14T08:11:58-07:00全身型重症筋無力症の増悪とレスキュー療法を大幅に抑制：第3相MINT試験からみたイネビリズマブの意義 https://news.medxy.ai/vi/inebilizumab-efficacy-myasthenia-gravis/Medxy AIvi2026-08-14T08:11:34-07:00Inebilizumab cho thấy hiệu quả vượt trội trong giảm đợt kịch phát và nhu cầu cứu hộ ở nhược cơ toàn thân: Kết quả từ thử nghiệm pha 3 MINT https://news.medxy.ai/inebilizumab-significantly-reduces-exacerbations-and-need-for-rescue-therapy-in-generalized-myasthenia-gravis-insights-from-the-phase-3-mint-trial/Medxy AIen2026-08-14T08:08:12-07:00Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial https://news.medxy.ai/zh/liver-transplant-colorectal-cancer/Medxy AIzh2026-08-14T08:06:51-07:00结直肠癌不可切除肝转移的肝移植：SECA-II研究揭示长期生存与潜在治愈价值 https://news.medxy.ai/ja/liver-transplant-colon-cancer/Medxy AIja2026-08-14T08:06:34-07:00切除不能な大腸癌肝限局転移に対する肝移植の長期生存と根治可能性：SECA-II研究からの示唆 https://news.medxy.ai/vi/liver-transplant-colorectal-cancer-2/Medxy AIvi2026-08-14T08:06:14-07:00Ghép gan cho di căn gan do ung thư đại trực tràng không thể cắt bỏ: thời gian sống lâu dài và tiềm năng khỏi bệnh từ nghiên cứu SECA-II https://news.medxy.ai/long-term-survival-and-curative-potential-of-liver-transplantation-for-nonresectable-colorectal-liver-metastases-insights-from-the-seca-ii-study/Medxy AIen2026-08-14T08:04:54-07:00Long-Term Survival and Curative Potential of Liver Transplantation for Nonresectable Colorectal Liver Metastases: Insights from the SECA-II Study https://news.medxy.ai/zh/antiplatelet-use-after-ich/Medxy AIzh2026-08-14T08:04:37-07:00ICH 后能否用抗血小板药？STATICH 试验给出的风险与获益信号 https://news.medxy.ai/ja/antiplatelet-therapy-after-ich/Medxy AIja2026-08-14T08:04:11-07:00ICH後の抗血小板療法をどう考えるか：STATICH試験が示したリスクと利益の均衡 https://news.medxy.ai/vi/antiplatelet-therapy-risk-balance/Medxy AIvi2026-08-14T08:03:49-07:00Cân bằng nguy cơ: Điều trị kháng kết tập tiểu cầu sau xuất huyết nội sọ trong thử nghiệm STATICH https://news.medxy.ai/balancing-risks-antiplatelet-therapy-after-intracerebral-haemorrhage-in-the-statich-trial/Medxy AIen2026-08-14T08:02:21-07:00Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH Trial https://news.medxy.ai/zh/military-trauma-triage/Medxy AIzh2026-08-14T08:02:00-07:00军事创伤二元分诊系统简化评估：准确性与作战可行性的平衡 https://news.medxy.ai/ja/military-trauma-triage-2/Medxy AIja2026-08-14T08:01:32-07:00軍事外傷における簡略化二択トリアージの有用性を検証する：精度と運用実現性の両立 https://news.medxy.ai/vi/military-trauma-priority-classification/Medxy AIvi2026-08-14T08:01:04-07:00Đánh giá hệ thống phân loại ưu tiên nhị phân đơn giản hóa trong chấn thương quân sự: Cân bằng giữa độ chính xác và tính khả thi trong tác chiến https://news.medxy.ai/evaluating-a-simplified-binary-triage-system-for-military-trauma-balancing-accuracy-and-operational-feasibility/Medxy AIen2026-08-14T07:59:28-07:00Evaluating a Simplified Binary Triage System for Military Trauma: Balancing Accuracy and Operational Feasibility https://news.medxy.ai/zh/lung-cancer-surgery-range/Medxy AIzh2026-08-14T07:59:02-07:00非小细胞肺癌切除范围与切缘阳性的关系：手术范围并非决定因素 https://news.medxy.ai/ja/impact-resection-nsclc/Medxy AIja2026-08-14T07:58:46-07:00非小細胞肺癌における切除範囲の影響：断端陽性は術式に左右されない https://news.medxy.ai/vi/non-small-cell-lung-cancer/Medxy AIvi2026-08-14T07:58:24-07:00Ung thư phổi không tế bào nhỏ: bờ cắt dương tính không phụ thuộc phạm vi phẫu thuật https://news.medxy.ai/resection-extent-in-non-small-cell-lung-cancer-margin-positivity-is-unrelated-to-surgical-scope/Medxy AIen2026-08-14T07:57:10-07:00Resection Extent in Non-Small Cell Lung Cancer: Margin Positivity is Unrelated to Surgical Scope https://news.medxy.ai/zh/semaglutide-on-gestational-weight-gain-and-pregnancy-outcomes-in-obese-women/Medxy AIzh2026-08-14T07:56:47-07:00超重及肥胖女性暴露于司美格鲁肽对妊娠期体重增加及妊娠结局的影响 https://news.medxy.ai/ja/semaglutide-on-gestational-weight-gain-and-pregnancy-outcomes-in-overweight-and-obese-women/Medxy AIja2026-08-14T07:56:26-07:00過体重および肥満の女性におけるセマグルチド曝露が妊娠中の体重増加と妊娠転帰に及ぼす影響 https://news.medxy.ai/vi/semaglutide-pregnancy-weight/Medxy AIvi2026-08-14T07:56:04-07:00Phơi nhiễm semaglutide ảnh hưởng thế nào đến tăng cân thai kỳ và kết cục thai kỳ ở phụ nữ thừa cân, béo phì? https://news.medxy.ai/impact-of-semaglutide-exposure-on-gestational-weight-gain-and-pregnancy-outcomes-in-overweight-and-obese-women/Medxy AIen2026-08-14T07:54:13-07:00Impact of Semaglutide Exposure on Gestational Weight Gain and Pregnancy Outcomes in Overweight and Obese Women https://news.medxy.ai/zh/crohns-disease-additives/Medxy AIzh2026-08-14T07:53:51-07:00克罗恩病中人工甜味剂与乳化剂的新发现：来自 ENIGMA 研究的生物标志物与代谢机制 https://news.medxy.ai/ja/artificial-sweeteners-and-emulsifiers-in-crohns-disease/Medxy AIja2026-08-14T07:53:33-07:00クローン病における人工甘味料と乳化剤に関する新たな知見：ENIGMA研究から得られたバイオマーカーと代謝メカニズム https://news.medxy.ai/vi/crohns-food-additives/Medxy AIvi2026-08-14T07:53:12-07:00Bệnh Crohn và phụ gia thực phẩm: phát hiện mới về chất tạo ngọt nhân tạo, chất nhũ hóa và dấu ấn sinh học từ nghiên cứu ENIGMA https://news.medxy.ai/new-insights-into-artificial-sweeteners-and-emulsifiers-in-crohns-disease-biomarkers-and-metabolic-mechanisms-from-the-enigma-study/Medxy AIen2026-08-14T07:51:50-07:00New Insights into Artificial Sweeteners and Emulsifiers in Crohn’s Disease: Biomarkers and Metabolic Mechanisms from the ENIGMA Study https://news.medxy.ai/zh/cardiovascular-kidney-metabolic-syndrome-masld-fibrosis-risk/Medxy AIzh2026-08-14T07:51:28-07:00心血管—肾脏—代谢综合征与MASLD中肝纤维化进展及肝相关事件风险 https://news.medxy.ai/ja/masld-cardiovascular-renal-metabolic-syndrome/Medxy AIja2026-08-14T07:51:07-07:00MASLDにおける心血管・腎・代謝症候群と肝線維化進行・肝関連イベントへの影響 https://news.medxy.ai/vi/cardiorenal-metabolic-syndrome/Medxy AIvi2026-08-14T07:50:35-07:00Hội chứng tim mạch-thận-chuyển hóa và tác động của nó lên tiến triển xơ hóa gan cùng các biến cố liên quan đến gan trong MASLD https://news.medxy.ai/cardiovascular-kidney-metabolic-syndrome-and-its-impact-on-liver-fibrosis-progression-and-liver-related-events-in-masld/Medxy AIen2026-08-14T07:48:59-07:00Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD https://news.medxy.ai/zh/daromun-melanoma/Medxy AIzh2026-08-13T22:03:02-07:00新辅助瘤内 Daromun 显著改善可切除 III 期黑色素瘤预后——PIVOTAL III 期试验更新解读 https://news.medxy.ai/ja/daromun-melanoma-2/Medxy AIja2026-08-13T22:02:43-07:00切除可能な第III期メラノーマに術前病変内Daromunが有望：PIVOTAL第III相試験更新で明らかになった効果 https://news.medxy.ai/vi/adjuvant-immunotherapy-melanoma/Medxy AIvi2026-08-13T22:02:18-07:00Daromun tân bổ trợ tiêm nội tổn thương cho thấy cải thiện rõ rệt kết cục ở u hắc tố giai đoạn III có thể cắt bỏ: cập nhật từ thử nghiệm pha III PIVOTAL https://news.medxy.ai/neoadjuvant-intralesional-daromun-significantly-improves-outcomes-in-resectable-stage-iii-melanoma-insights-from-the-pivotal-phase-iii-trial-update/Medxy AIen2026-08-13T22:01:06-07:00Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update https://news.medxy.ai/zh/age-prognosis-glioma/Medxy AIzh2026-08-13T21:52:16-07:00分子分型低级别胶质瘤中年龄作为预后指标的再评估 https://news.medxy.ai/ja/low-grade-glioma-age-prognosis/Medxy AIja2026-08-13T21:52:00-07:00分子病理で見直す低悪性度神経膠腫の年齢と予後 https://news.medxy.ai/vi/age-prognosis-low-grade-glioma/Medxy AIvi2026-08-13T21:51:38-07:00Xem xét lại vai trò của tuổi như một dấu ấn tiên lượng trong u thần kinh đệm độ thấp được xác định về mặt phân tử https://news.medxy.ai/reevaluating-age-as-a-prognostic-marker-in-molecularly-defined-lower-grade-gliomas/Medxy AIen2026-08-13T21:50:40-07:00Reevaluating Age as a Prognostic Marker in Molecularly Defined Lower-Grade Gliomas https://news.medxy.ai/zh/thyroid-nodule-sign/Medxy AIzh2026-08-13T18:28:31-07:00甲状腺结节周边间断点状强回声灶：高度提示乳头状甲状腺癌的新型超声征象 https://news.medxy.ai/vi/peripheral-microcalcifications/Medxy AIvi2026-08-13T18:28:04-07:00Các ổ tăng âm chấm nhỏ ngoại vi không liên tục: dấu ấn siêu âm mới gợi ý mạnh ung thư biểu mô tuyến giáp thể nhú https://news.medxy.ai/discontinuous-peripheral-punctate-echogenic-foci-a-novel-ultrasound-marker-highly-suggestive-of-papillary-thyroid-carcinoma/Medxy AIen2026-08-13T18:27:23-07:00Discontinuous Peripheral Punctate Echogenic Foci: A Novel Ultrasound Marker Highly Suggestive of Papillary Thyroid Carcinoma https://news.medxy.ai/zh/heart-failure-risk-diabetes-2/Medxy AIzh2026-08-13T18:27:04-07:00新诊断糖尿病中的心力衰竭风险：胰岛素抵抗与肾功能为何如此关键 https://news.medxy.ai/ja/unveiling-heart-failure-risks-in-newly-diagnosed-diabetes-insulin-resistance-and-renal-function/Medxy AIja2026-08-13T18:26:49-07:00新規診断された糖尿病における心不全リスクの解明：インスリン抵抗性と腎機能の重要な役割 https://news.medxy.ai/vi/heart-failure-risk-diabetes/Medxy AIvi2026-08-13T18:26:32-07:00Phát hiện nguy cơ suy tim ở người mới chẩn đoán đái tháo đường: Vai trò then chốt của đề kháng insulin và chức năng thận https://news.medxy.ai/unveiling-heart-failure-risks-in-newly-diagnosed-diabetes-the-critical-role-of-insulin-resistance-and-renal-function/Medxy AIen2026-08-13T18:25:50-07:00Unveiling Heart Failure Risks in Newly Diagnosed Diabetes: The Critical Role of Insulin Resistance and Renal Function https://news.medxy.ai/zh/vosoritide-growth-rasopathy/Medxy AIzh2026-08-13T18:25:32-07:00vosoritide 在 RASopathy 及相关遗传性矮身材患儿中显示出令人鼓舞的促生长作用 https://news.medxy.ai/ja/vosoritide-shows-growth-benefits-in-children-with-rasopathies-and-related-genetic-short-stature-disorders/Medxy AIja2026-08-13T18:25:16-07:00ヴォソリチド、RASopathies（ラスオパチー）および関連する遺伝性低身長症の小児において有望な成長促進効果を示す https://news.medxy.ai/vi/vosoritide-growth-benefits/Medxy AIvi2026-08-13T18:24:58-07:00Vosoritide cho thấy lợi ích tăng trưởng đầy hứa hẹn ở trẻ mắc RASopathy và các rối loạn thấp lùn di truyền liên quan https://news.medxy.ai/vosoritide-shows-promising-growth-benefits-in-children-with-rasopathies-and-related-genetic-short-stature-disorders/Medxy AIen2026-08-13T18:23:38-07:00Vosoritide Shows Promising Growth Benefits in Children with RASopathies and Related Genetic Short Stature Disorders https://news.medxy.ai/ja/gda-hba1c-correction/Medxy AIja2026-08-13T18:23:18-07:00CGM指標とHbA1cのずれを補正するGDAC研究：糖尿病診療に向けた個別化HbA1c補正の意義 https://news.medxy.ai/vi/personalized-hba1c-adjustment/Medxy AIvi2026-08-13T18:23:02-07:00Nghiên cứu GDAC về hiệu chỉnh HbA1c cá thể hóa dựa trên glucose: Cải thiện sự phù hợp giữa chỉ số từ CGM và HbA1c ở các cá thể và nhóm chủng tộc khác nhau mắc đái tháo đường, gợi ý cho thực hành lâm sàng https://news.medxy.ai/glucose-derived-personalized-hba1c-correction-gdac-study-to-improve-alignment-between-cgm-derived-metrics-and-hba1c-in-different-individuals-and-racial-groups-with-diabetes-implications-for-clinica/Medxy AIen2026-08-13T18:21:59-07:00Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice https://news.medxy.ai/zh/dynamic-metabolic-profiling-in-chronic-heart-failure/Medxy AIzh2026-08-13T18:21:41-07:00慢性心力衰竭中的动态代谢谱分析：基于连续核磁共振（NMR）生物标志物及风险预测的启示 https://news.medxy.ai/ja/chronic-heart-failure-metabolism/Medxy AIja2026-08-13T18:21:24-07:00慢性心不全における動的代謝プロファイリング：連続NMRバイオマーカーとリスク予測から得られた知見 https://news.medxy.ai/vi/metabolic-profiling-heart-failure/Medxy AIvi2026-08-13T18:21:05-07:00Lập hồ sơ chuyển hóa động trong suy tim mạn tính: Những phát hiện từ các dấu ấn sinh học NMR theo chuỗi thời gian và dự báo nguy cơ https://news.medxy.ai/dynamic-metabolic-profiling-in-chronic-heart-failure-insights-from-serial-nmr-biomarkers-and-risk-prediction/Medxy AIen2026-08-13T18:20:12-07:00Dynamic Metabolic Profiling in Chronic Heart Failure: Insights from Serial NMR Biomarkers and Risk Prediction https://news.medxy.ai/zh/oral-anticoagulants-cognition-and-clinical-outcomes-in-atrial-fibrillation-and-alzheimers-disease/Medxy AIzh2026-08-13T18:19:56-07:00房颤与阿尔茨海默病患者中的口服抗凝药、认知功能及临床结局的关联：一项瑞典全国性研究 https://news.medxy.ai/ja/afib-alzheimers-study/Medxy AIja2026-08-13T18:19:32-07:00心房細動とアルツハイマー病における経口抗凝固薬、認知機能、臨床転帰――スウェーデン全国規模研究が示す知見 https://news.medxy.ai/vi/oral-anticoagulants-alzheimers/Medxy AIvi2026-08-13T18:19:08-07:00Thuốc chống đông đường uống, nhận thức và kết cục lâm sàng ở rung nhĩ kèm bệnh Alzheimer: Những phát hiện từ một nghiên cứu toàn quốc tại Thụy Điển https://news.medxy.ai/oral-anticoagulants-cognition-and-clinical-outcomes-in-atrial-fibrillation-and-alzheimers-disease-insights-from-a-swedish-nationwide-study/Medxy AIen2026-08-13T18:17:08-07:00Oral Anticoagulants, Cognition, and Clinical Outcomes in Atrial Fibrillation and Alzheimer’s Disease: Insights from a Swedish Nationwide Study https://news.medxy.ai/ja/transthyretin-amyloid-cardiomyopathy/Medxy AIja2026-08-13T18:16:34-07:00トランスサイレチンアミロイド心筋症の疾患進行を捉え直す――機序特異的モニタリングと治療反応評価へ https://news.medxy.ai/vi/redefining-disease-progression/Medxy AIvi2026-08-13T18:16:13-07:00Tái định nghĩa tiến triển bệnh trong bệnh cơ tim amyloid transthyretin: Hướng tới theo dõi theo cơ chế và đánh giá đáp ứng điều trị https://news.medxy.ai/rethinking-disease-progression-in-transthyretin-amyloid-cardiomyopathy-toward-mechanism-specific-monitoring-and-therapeutic-response-assessment/Medxy AIen2026-08-13T18:15:31-07:00Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy: Toward Mechanism-Specific Monitoring and Therapeutic Response Assessment https://news.medxy.ai/zh/enzyme-assay-hba2/Medxy AIzh2026-08-13T17:57:12-07:00酶学测定 2-羟基丁酸助力血糖异常筛查：超越传统空腹指标的新进展 https://news.medxy.ai/ja/dysglycemia-screening/Medxy AIja2026-08-13T17:56:56-07:00dysglycemiaスクリーニングを前進させる：2-ヒドロキシ酪酸の酵素測定が従来の空腹時指標を超える検出能を実現 https://news.medxy.ai/vi/2-hydroxybutyrate-test/Medxy AIvi2026-08-13T17:56:07-07:00Đo 2-Hydroxybutyrate bằng xét nghiệm enzym: Bước tiến mới trong sàng lọc rối loạn đường huyết vượt ngoài xét nghiệm lúc đói https://news.medxy.ai/enzymatic-2-hydroxybutyrate-assay-a-novel-screening-tool-to-detect-dysglycemia-beyond-standard-fasting-tests/Medxy AIen2026-08-13T08:12:01-07:00Enzymatic 2-Hydroxybutyrate Assay: A Novel Screening Tool to Detect Dysglycemia Beyond Standard Fasting Tests https://news.medxy.ai/zh/fetal-cardiomyopathy/Medxy AIzh2026-08-13T08:09:32-07:00多中心北美队列揭示胎儿心肌病的预后进展与风险线索 https://news.medxy.ai/ja/fetal-cardiomyopathy-prognosis/Medxy AIja2026-08-13T08:09:01-07:00胎児心筋症の転帰と予後を読み解く：北米多施設コホートから見えた最新知見 https://news.medxy.ai/vi/fetal-cardiomyopathy-2/Medxy AIvi2026-08-13T08:07:18-07:00Bệnh cơ tim thai nhi trong kỷ nguyên hiện đại: tiến triển và những dấu ấn tiên lượng từ một đoàn hệ đa trung tâm Bắc Mỹ https://news.medxy.ai/progress-and-prognostic-insights-in-fetal-cardiomyopathy-findings-from-a-multicenter-north-american-cohort/Medxy AIen2026-08-13T08:03:35-07:00Progress and Prognostic Insights in Fetal Cardiomyopathy: Findings from a Multicenter North American Cohort https://news.medxy.ai/zh/vutrisiran-in-cardiac-structure-function-and-amyloid-burden-in-attr-cm/Medxy AIzh2026-08-13T08:02:41-07:00Vutrisiran 治疗与 ATTR-CM 患者心脏结构、功能及淀粉样蛋白负荷的心血管 MRI 变化 https://news.medxy.ai/ja/vutrisiran-attr-cm-mri/Medxy AIja2026-08-13T08:02:19-07:00Vutrisiran治療がATTR-CMの心構造・心機能・アミロイド負荷に及ぼす影響を心血管MRIで検証 https://news.medxy.ai/vi/vutrisiran-mri-amyloid/Medxy AIvi2026-08-13T08:01:43-07:00Vutrisiran và những thay đổi trên MRI tim mạch ở bệnh cơ tim amyloid transthyretin: cấu trúc, chức năng và gánh nặng amyloid https://news.medxy.ai/vutrisiran-treatment-and-cardiovascular-mri-detected-changes-in-cardiac-structure-function-and-amyloid-burden-in-attr-cm/Medxy AIen2026-08-13T07:58:51-07:00Vutrisiran Treatment and Cardiovascular MRI-Detected Changes in Cardiac Structure, Function, and Amyloid Burden in ATTR-CM https://news.medxy.ai/zh/beyond-bmi-waist-hip/Medxy AIzh2026-08-13T07:58:06-07:00超越BMI：腰围与腰臀比如何提升心血管风险预测 https://news.medxy.ai/ja/bmi-waist-hip-risk/Medxy AIja2026-08-13T07:57:43-07:00BMIだけでは不十分：ウエスト周囲径とウエスト・ヒップ比が心血管リスク予測をどう高めるか https://news.medxy.ai/vi/beyond-bmi-waist-hip-ratio/Medxy AIvi2026-08-13T07:57:16-07:00Vượt ra ngoài BMI: Vòng eo và tỷ lệ vòng eo/hông giúp dự đoán nguy cơ tim mạch chính xác hơn https://news.medxy.ai/beyond-bmi-how-waist-circumference-and-waist-to-hip-ratio-enhance-cardiovascular-risk-prediction/Medxy AIen2026-08-13T07:55:31-07:00Beyond BMI: How Waist Circumference and Waist-to-Hip Ratio Enhance Cardiovascular Risk Prediction https://news.medxy.ai/zh/myasthenia-gravis-antibody-test/Medxy AIzh2026-08-13T07:27:00-07:00重症肌无力抗体检测方法如何选？ADAM研究带来新证据 https://news.medxy.ai/ja/myasthenia-gravis-antibody-test-2/Medxy AIja2026-08-13T07:26:29-07:00重症筋無力症における抗体検査法を再考する：ADAM研究が示した知見 https://news.medxy.ai/vi/antibody-detection-myasthenia/Medxy AIvi2026-08-13T07:26:05-07:00Đánh giá các phương pháp phát hiện kháng thể trong bệnh nhược cơ: Những phát hiện từ nghiên cứu ADAM https://news.medxy.ai/evaluating-antibody-detection-methods-in-myasthenia-gravis-insights-from-the-adam-study/Medxy AIen2026-08-13T07:23:59-07:00Evaluating Antibody Detection Methods in Myasthenia Gravis: Insights from the ADAM Study https://news.medxy.ai/zh/fibroscan-liver-stiffness/Medxy AIzh2026-08-13T07:19:37-07:00Fibroscan® 肝脏硬度测量在原发性硬化性胆管炎预后评估中的价值：前瞻性 FICUS 队列研究新发现 https://news.medxy.ai/vi/liver-stiffness-prediction-2/Medxy AIvi2026-08-13T07:18:44-07:00Đo độ cứng gan có thực sự dự báo tiên lượng trong viêm đường mật xơ hóa nguyên phát? Dữ liệu từ đoàn hệ FICUS tiền cứu https://news.medxy.ai/validating-liver-stiffness-measurement-as-a-prognostic-tool-in-primary-sclerosing-cholangitis-insights-from-the-prospective-ficus-cohort/Medxy AIen2026-08-13T07:16:24-07:00Validating Liver Stiffness Measurement as a Prognostic Tool in Primary Sclerosing Cholangitis: Insights from the Prospective FICUS Cohort https://news.medxy.ai/zh/braf-v600-melanoma-survival/Medxy AIzh2026-08-13T00:09:57-07:00BRAF V600 突变晚期黑色素瘤中 Spartalizumab 联合 Dabrafenib 与 Trametinib 的长期生存获益：COMBI-I 试验启示 https://news.medxy.ai/ja/braf-v600-spartalizumab-benefit/Medxy AIja2026-08-13T00:09:32-07:00BRAF V600変異陽性進行悪性黒色腫におけるspartalizumab併用の長期生存ベネフィット：COMBI-I試験からの知見 https://news.medxy.ai/vi/spartalizumab-braf-trial/Medxy AIvi2026-08-13T00:09:09-07:00Spartalizumab kết hợp dabrafenib và trametinib mang lại lợi ích sống còn dài hạn ở u hắc tố tiến triển mang đột biến BRAF V600: Kết quả từ thử nghiệm COMBI-I https://news.medxy.ai/long-term-survival-benefit-of-spartalizumab-with-dabrafenib-and-trametinib-in-braf-v600-mutant-advanced-melanoma-insights-from-the-combi-i-trial/Medxy AIen2026-08-13T00:07:37-07:00Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial https://news.medxy.ai/zh/left-atrial-volume-index-2/Medxy AIzh2026-08-12T10:49:58-07:00移植前左心房容积指数：预测肾移植后1年发病风险的新线索 https://news.medxy.ai/vi/left-atrial-volume-index/Medxy AIvi2026-08-12T10:49:13-07:00Chỉ số thể tích nhĩ trái trước ghép: Dấu ấn dự báo bệnh suất 1 năm sau ghép thận https://news.medxy.ai/pre-transplant-left-atrial-volume-index-as-a-predictor-of-one-year-morbidity-after-kidney-transplantation-insights-and-implications/Medxy AIen2026-08-12T10:47:07-07:00Pre-Transplant Left Atrial Volume Index as a Predictor of One-Year Morbidity after Kidney Transplantation: Insights and Implications https://news.medxy.ai/ja/donor-pancreas-transplant/Medxy AIja2026-08-12T10:46:22-07:00循環死後ドナー膵・膵島移植を変える常温区域灌流の可能性 https://news.medxy.ai/vi/body-circulation-physiology/Medxy AIvi2026-08-12T10:45:57-07:00Tuần hoàn vùng cơ thể ở nhiệt độ sinh lý: Bước ngoặt trong ghép tụy và ghép tiểu đảo tụy từ người hiến DCD https://news.medxy.ai/normothermic-regional-perfusion-a-paradigm-shift-in-pancreas-and-islet-transplantation-from-dcd-donors/Medxy AIen2026-08-12T10:45:01-07:00Normothermic Regional Perfusion: A Paradigm Shift in Pancreas and Islet Transplantation from DCD Donors https://news.medxy.ai/vi/pyoderma-gangrenosum-classification/Medxy AIvi2026-08-12T10:44:05-07:00Pyoderma gangrenosum: Khung phân loại thực hành từ đồng thuận chuyên gia https://news.medxy.ai/a-practical-framework-for-pyoderma-gangrenosum-expert-consensus-defines-phenotypes-and-modifiers/Medxy AIen2026-08-12T10:40:15-07:00A Practical Framework for Pyoderma Gangrenosum: Expert Consensus Defines Phenotypes and Modifiers https://news.medxy.ai/zh/confocal-microscopy-prediction/Medxy AIzh2026-08-12T10:39:57-07:00反射式共聚焦显微镜与深度学习助力面部特应性皮炎患者度普利尤单抗疗效的早期预测 https://news.medxy.ai/ja/dupilumab-effect-prediction/Medxy AIja2026-08-12T10:39:39-07:00反射型共焦点顕微鏡と深層学習による顔面アトピー性皮膚炎におけるデュピルマブ効果の早期予測 https://news.medxy.ai/vi/early-dupilumab-prediction/Medxy AIvi2026-08-12T10:39:19-07:00Dự đoán sớm hiệu quả của dupilumab trong viêm da cơ địa vùng mặt bằng kính hiển vi đồng tiêu phản xạ và học sâu https://news.medxy.ai/early-prediction-of-dupilumab-efficacy-in-facial-atopic-dermatitis-via-reflectance-confocal-microscopy-and-deep-learning/Medxy AIen2026-08-12T10:38:31-07:00Early Prediction of Dupilumab Efficacy in Facial Atopic Dermatitis via Reflectance Confocal Microscopy and Deep Learning https://news.medxy.ai/zh/breast-augmentation-analysis-2/Medxy AIzh2026-08-12T10:38:13-07:00组织保留与三维几何分析优化隆胸：临床要点与结局 https://news.medxy.ai/ja/breast-augmentation-analysis/Medxy AIja2026-08-12T10:37:55-07:00組織温存と3D幾何解析で磨く乳房増大術：臨床知見とその成果 https://news.medxy.ai/vi/breast-augmentation-3d-analysis/Medxy AIvi2026-08-12T10:37:25-07:00Nâng ngực tối ưu hóa nhờ bảo tồn mô và phân tích hình học 3D: góc nhìn lâm sàng và kết quả https://news.medxy.ai/optimizing-breast-augmentation-through-tissue-preservation-and-3d-geometric-analysis-clinical-insights-and-outcomes/Medxy AIen2026-08-12T10:36:13-07:00Optimizing Breast Augmentation Through Tissue Preservation and 3D Geometric Analysis: Clinical Insights and Outcomes https://news.medxy.ai/zh/botox-strategy-optimization/Medxy AIzh2026-08-12T10:35:53-07:00优化口角上提的肉毒毒素注射策略：一项严格两阶段随机试验的启示 https://news.medxy.ai/ja/botulinum-toxin-optimization-2/Medxy AIja2026-08-12T10:35:33-07:00口角挙上を最適化するボツリヌス毒素注射：厳密な2段階ランダム化試験から得られた知見 https://news.medxy.ai/vi/botulinum-toxin-optimization/Medxy AIvi2026-08-12T10:35:15-07:00Tối ưu hóa tiêm Botulinum toxin để nâng khóe miệng: Những phát hiện từ một thử nghiệm ngẫu nhiên hai giai đoạn nghiêm ngặt https://news.medxy.ai/optimizing-botulinum-toxin-injections-for-oral-commissure-elevation-insights-from-a-rigorous-two-stage-randomized-trial/Medxy AIen2026-08-12T10:34:01-07:00Optimizing Botulinum Toxin Injections for Oral Commissure Elevation: Insights from a Rigorous Two-Stage Randomized Trial https://news.medxy.ai/zh/childhood-trauma-bipolar-2/Medxy AIzh2026-08-12T10:33:40-07:00揭示儿童期创伤与躁郁症之间的神经生物学通路：来自 ENIGMA 联盟的研究见解 https://news.medxy.ai/vi/childhood-trauma-bipolar/Medxy AIvi2026-08-12T10:32:55-07:00Giải mã các con đường thần kinh sinh học nối sang chấn thời thơ ấu với rối loạn lưỡng cực: Góc nhìn từ ENIGMA Consortium https://news.medxy.ai/unraveling-the-neurobiological-pathways-linking-childhood-trauma-to-bipolar-disorder-insights-from-the-enigma-consortium/Medxy AIen2026-08-12T10:31:47-07:00Unraveling the Neurobiological Pathways Linking Childhood Trauma to Bipolar Disorder: Insights from the ENIGMA Consortium https://news.medxy.ai/zh/vasopressin-timing-sepsis/Medxy AIzh2026-08-12T10:31:30-07:00脓毒性休克中去甲肾上腺素升级后：超早期启动加压素是否优于早期启动？来自目标试验模拟的启示 https://news.medxy.ai/ja/vasopressin-sepsis-shock/Medxy AIja2026-08-12T10:31:12-07:00敗血症性ショックにおけるノルアドレナリン増量後のバソプレシン早期導入：ターゲットトライアル・エミュレーションからの知見 https://news.medxy.ai/vi/early-vasopressin-treatment/Medxy AIvi2026-08-12T10:30:52-07:00Khởi trị vasopressin siêu sớm sau khi tăng norepinephrine trong sốc nhiễm khuẩn: bằng chứng từ mô phỏng thử nghiệm mục tiêu https://news.medxy.ai/ultra-early-versus-early-vasopressin-initiation-after-norepinephrine-escalation-in-septic-shock-insights-from-a-target-trial-emulation/Medxy AIen2026-08-12T10:29:46-07:00Ultra-Early Versus Early Vasopressin Initiation After Norepinephrine Escalation in Septic Shock: Insights from a Target Trial Emulation https://news.medxy.ai/zh/icu-rrt-benefits-risks/Medxy AIzh2026-08-12T10:29:28-07:00ICU重症患者RRT的获益与风险：日本登记研究揭示治疗效应的复杂异质性 https://news.medxy.ai/ja/icu-renal-therapy-benefits-risks/Medxy AIja2026-08-12T10:29:10-07:00ICU重症患者における腎代替療法の利益とリスクを読み解く：日本レジストリからの知見 https://news.medxy.ai/vi/kidney-replacement-icu/Medxy AIvi2026-08-12T10:28:49-07:00Làm rõ lợi ích và nguy cơ phức tạp của liệu pháp thay thế thận ở bệnh nhân ICU: Góc nhìn từ một cơ sở đăng ký của Nhật Bản https://news.medxy.ai/unraveling-the-complex-benefits-and-risks-of-renal-replacement-therapy-in-icu-patients-insights-from-a-japanese-registry/Medxy AIen2026-08-12T10:28:00-07:00Unraveling the Complex Benefits and Risks of Renal Replacement Therapy in ICU Patients: Insights from a Japanese Registry https://news.medxy.ai/zh/empowering-internal-medicine-residents/Medxy AIzh2026-08-12T10:27:42-07:00赋能内科住院医师应对肥胖：资源不足城市门诊中的综合培训路径 https://news.medxy.ai/ja/obesity-care-clinic/Medxy AIja2026-08-12T10:27:23-07:00都市部の十分な医療資源が行き届きにくい診療所で進める肥満症対策：総合内科レジデント育成の包括的研修パス https://news.medxy.ai/vi/empowering-resident-physicians/Medxy AIvi2026-08-12T10:26:59-07:00Trao quyền cho bác sĩ nội trú nội khoa trong cuộc chiến chống béo phì: một lộ trình đào tạo toàn diện tại phòng khám đô thị thiếu nguồn lực https://news.medxy.ai/empowering-internal-medicine-residents-to-combat-obesity-a-comprehensive-training-pathway-in-an-underserved-urban-clinic/Medxy AIen2026-08-12T10:25:57-07:00Empowering Internal Medicine Residents to Combat Obesity: A Comprehensive Training Pathway in an Underserved Urban Clinic https://news.medxy.ai/zh/lung-cancer-screening-2/Medxy AIzh2026-08-12T10:25:40-07:00提升肺癌筛查依从性：来自健康沟通与分层提醒干预随机临床试验的启示 https://news.medxy.ai/ja/lung-cancer-screening/Medxy AIja2026-08-12T10:25:19-07:00肺がん検診の受診継続率を高めるには：健康コミュニケーションと段階的リマインダー介入のランダム化試験から得られた知見 https://news.medxy.ai/enhancing-lung-cancer-screening-adherence-insights-from-a-randomized-clinical-trial-of-health-communication-and-stepped-reminder-interventions/Medxy AIen2026-08-12T10:23:21-07:00Enhancing Lung Cancer Screening Adherence: Insights from a Randomized Clinical Trial of Health Communication and Stepped Reminder Interventions https://news.medxy.ai/zh/hallux-rigidus-surgery/Medxy AIzh2026-08-12T10:23:02-07:00拇趾僵硬症：手术融合术优于观察等待吗？——一项里程碑式随机对照试验的启示 https://news.medxy.ai/vi/arthrodesis-vs-waiting/Medxy AIvi2026-08-12T10:22:23-07:00Arthrodesis phẫu thuật hay theo dõi chờ đợi trong hallux rigidus: Góc nhìn từ một thử nghiệm ngẫu nhiên có đối chứng mang tính bước ngoặt https://news.medxy.ai/surgical-arthrodesis-versus-watchful-waiting-in-hallux-rigidus-insights-from-a-landmark-randomized-controlled-trial/Medxy AIen2026-08-12T10:21:38-07:00Surgical Arthrodesis Versus Watchful Waiting in Hallux Rigidus: Insights from a Landmark Randomized Controlled Trial https://news.medxy.ai/zh/sos-vod-incidence-risk-factors/Medxy AIzh2026-08-12T10:21:17-07:00成人异基因HSCT后SOS/VOD的真实世界发生率、危险因素与生物标志物验证：来自西班牙GETH-TC登记的证据 https://news.medxy.ai/vi/sos-vod-incidence-risk/Medxy AIvi2026-08-12T10:20:36-07:00Tỷ lệ mắc thực tế, yếu tố nguy cơ và xác thực dấu ấn sinh học SOS/VOD sau ghép đồng loài ở người lớn: Dữ liệu từ cơ sở đăng ký GETH-TC của Tây Ban Nha https://news.medxy.ai/real-world-incidence-risk-factors-and-biomarker-validation-for-sos-vod-after-allogeneic-hsct-in-adults-insights-from-the-spanish-geth-tc-registry/Medxy AIen2026-08-12T10:19:45-07:00Real-World Incidence, Risk Factors, and Biomarker Validation for SOS/VOD After Allogeneic HSCT in Adults: Insights from the Spanish GETH-TC Registry https://news.medxy.ai/zh/lenalidomide-azacitidine-radiotherapy/Medxy AIzh2026-08-12T10:19:23-07:00来那度胺与口服阿扎胞苷联合放疗治疗浆细胞瘤：一项先导试验及展望 https://news.medxy.ai/ja/lenalidomide-azacitidine-radiation/Medxy AIja2026-08-12T10:19:05-07:00形質細胞腫に対するレナリドミドと経口アザシチジン併用放射線治療：パイロット試験と今後の展望 https://news.medxy.ai/lenalidomide-and-oral-azacitidine-combined-with-radiotherapy-in-plasmacytoma-a-pilot-trial-and-perspectives/Medxy AIen2026-08-12T10:16:23-07:00Lenalidomide and Oral Azacitidine Combined with Radiotherapy in Plasmacytoma: A Pilot Trial and Perspectives https://news.medxy.ai/zh/usp8-b-cell-myeloma/Medxy AIzh2026-08-12T10:16:03-07:00USP8：B 细胞蛋白稳态与多发性骨髓瘤耐药的新靶点 https://news.medxy.ai/ja/b-cell-proteostasis-myeloma/Medxy AIja2026-08-12T10:15:45-07:00USP8を標的としたB細胞プロテオスタシスと多発性骨髄腫耐性の克服 https://news.medxy.ai/vi/usp8-potential-target/Medxy AIvi2026-08-12T10:15:24-07:00USP8: Đích điều trị tiềm năng trong proteostasis tế bào B và kháng đa u tủy https://news.medxy.ai/usp8-as-a-therapeutic-target-in-b-cell-proteostasis-and-multiple-myeloma-resistance/Medxy AIen2026-08-12T10:13:17-07:00USP8 as a Therapeutic Target in B Cell Proteostasis and Multiple Myeloma Resistance https://news.medxy.ai/zh/l-carnitine-regulation/Medxy AIzh2026-08-12T10:02:25-07:00l-肉碱调控人造血干/祖细胞再生的代谢机制：作用解析与治疗启示 https://news.medxy.ai/ja/l-carnitine-hematopoiesis/Medxy AIja2026-08-12T10:02:09-07:00l-カルニチンが切り開くヒト造血幹・前駆細胞再生の代謝制御：機序的洞察と治療応用 https://news.medxy.ai/zh/copd-beta-blocker-benefit/Medxy AIzh2026-08-12T09:59:50-07:00COPD合并心血管疾病患者使用β受体阻滞剂的生存获益：LABA联用的影响 https://news.medxy.ai/ja/beta-blockers-copd-cvd/Medxy AIja2026-08-12T09:59:33-07:00COPD合併心血管疾患におけるβ遮断薬の死亡率改善効果を読み解く：LABA併用の影響 https://news.medxy.ai/vi/beta-blockers-copd-benefits/Medxy AIvi2026-08-12T09:59:15-07:00Làm rõ lợi ích sống còn của thuốc chẹn beta ở bệnh nhân COPD có bệnh tim mạch: Ảnh hưởng của điều trị phối hợp LABA https://news.medxy.ai/unraveling-the-mortality-benefits-of-beta-blockers-in-copd-patients-with-cardiovascular-disease-influence-of-laba-co-therapy/Medxy AIen2026-08-12T09:57:46-07:00Unraveling the Mortality Benefits of Beta-Blockers in COPD Patients with Cardiovascular Disease: Influence of LABA Co-therapy https://news.medxy.ai/zh/post-tuberculosis-lung-damage/Medxy AIzh2026-08-12T09:57:25-07:00肺外结核后仍可持续受损：揭示结核后肺疾病的隐匿负担 https://news.medxy.ai/ja/post-tuberculosis-lung-damage-2/Medxy AIja2026-08-12T09:57:04-07:00肺外結核後も続く肺機能障害：見えにくい結核後肺疾患の負担を探る https://news.medxy.ai/vi/post-tb-lung-dysfunction/Medxy AIvi2026-08-12T09:56:41-07:00Rối loạn chức năng phổi kéo dài sau lao ngoài phổi: Làm rõ gánh nặng ẩn của bệnh phổi sau lao https://news.medxy.ai/persistent-lung-dysfunction-after-extra-pulmonary-tuberculosis-unveiling-the-hidden-burden-of-post-tb-lung-disease/Medxy AIen2026-08-12T09:55:29-07:00Persistent Lung Dysfunction After Extra-Pulmonary Tuberculosis: Unveiling the Hidden Burden of Post-TB Lung Disease https://news.medxy.ai/zh/scleral-fixation-iol/Medxy AIzh2026-08-12T09:55:11-07:00Yamane 巩膜内固定中的 IOL 公式屈光结局与预测准确性 https://news.medxy.ai/ja/yamane-iol-calculation/Medxy AIja2026-08-12T09:54:53-07:00Yamane強膜内固定におけるIOL度数計算式の屈折成績と予測精度 https://news.medxy.ai/vi/iol-power-prediction/Medxy AIvi2026-08-12T09:54:33-07:00Kết quả khúc xạ và độ chính xác dự đoán của các công thức tính công suất IOL trong cố định nội củng mạc theo Yamane https://news.medxy.ai/refractive-outcomes-and-predictive-accuracy-of-iol-power-formulas-in-yamane-intrascleral-fixation/Medxy AIen2026-08-12T09:53:18-07:00Refractive Outcomes and Predictive Accuracy of IOL Power Formulas in Yamane Intrascleral Fixation https://news.medxy.ai/ja/dual-focus-glasses-effectiveness/Medxy AIja2026-08-12T09:52:35-07:00小児近視抑制における双面複合デフォーカス眼鏡の有効性と安全性：エビデンスを総覧する https://news.medxy.ai/efficacy-and-safety-of-dual-sided-composite-defocus-spectacles-for-pediatric-myopia-control-a-comprehensive-evidence-review/Medxy AIen2026-08-12T09:50:16-07:00Efficacy and Safety of Dual-Sided Composite Defocus Spectacles for Pediatric Myopia Control: A Comprehensive Evidence Review https://news.medxy.ai/zh/tension-glottoplasty/Medxy AIzh2026-08-12T09:49:55-07:00张力性声门成形术：以生物力学创新推动声音女性化外科进展 https://news.medxy.ai/ja/voice-feminization-surgery/Medxy AIja2026-08-12T09:49:41-07:00張力付加声門形成術：生体力学的革新で切り開く声の女性化手術の新展開 https://news.medxy.ai/vi/tensioning-glottoplasty/Medxy AIvi2026-08-12T09:49:08-07:00Tensioning Glottoplasty: Bước tiến cơ sinh học trong phẫu thuật nữ tính hóa giọng nói https://news.medxy.ai/tensioning-glottoplasty-advancing-surgical-voice-feminization-with-biomechanical-innovation/Medxy AIen2026-08-12T09:47:57-07:00Tensioning Glottoplasty: Advancing Surgical Voice Feminization with Biomechanical Innovation https://news.medxy.ai/zh/robotic-pancreatectomy-assessment/Medxy AIzh2026-08-12T09:47:38-07:00日本全国机器人辅助远端胰切除术治疗恶性肿瘤的评估：安全性、结局与比较效果 https://news.medxy.ai/vi/robotic-distal-pancreatectomy-for-malignancy-safety-outcomes-and-comparative-effectiveness-in-japan/Medxy AIvi2026-08-12T09:47:00-07:00日本における悪性腫瘍に対するロボット支援下膵体尾部切除術の全国的評価：安全性、治療成績、および比較有効性 https://news.medxy.ai/nationwide-evaluation-of-robotic-distal-pancreatectomy-for-malignancy-safety-outcomes-and-comparative-effectiveness-in-japan/Medxy AIen2026-08-12T09:45:46-07:00Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan https://news.medxy.ai/zh/us-injury-healthcare-analysis/Medxy AIzh2026-08-12T09:45:16-07:00美国伤害医疗支出全景分析：致伤机制、人口学特征与支付方视角 https://news.medxy.ai/ja/us-injury-medical-costs/Medxy AIja2026-08-12T09:44:58-07:00米国の傷害医療費を総覧する：機序、人口学的特性、支払者の視点から https://news.medxy.ai/vi/us-injury-healthcare-spending/Medxy AIvi2026-08-12T09:44:33-07:00Phân tích toàn diện chi tiêu y tế do chấn thương tại Hoa Kỳ: cơ chế, đặc điểm nhân khẩu học và góc nhìn của bên chi trả